Development of hypoxia-sensitive Gd3+-based MRI contrast agents.

Area of Science:

• Medical Imaging
• Radiochemistry
• Biomedical Engineering

Background:

• Hypoxia, a condition of insufficient oxygen, is a critical factor in various diseases, including cancer and ischemia.
• Current diagnostic methods for hypoxia often lack sensitivity or specificity.
• Development of targeted imaging agents for hypoxia detection is crucial for disease management.

Purpose of the Study:

• To design and synthesize novel hypoxia-sensitive magnetic resonance imaging (MRI) contrast agents.
• To evaluate the performance of these agents in detecting hypoxic conditions.
• To establish a 'smart' MRI contrast agent for physiological hypoxia detection.

Main Methods:

• Synthesis of sulfonamide-based gadolinium (Gd(3+)) complexes (SAGds).
• Assessment of pH-dependent relaxivity (r(1)) changes.
• Evaluation of selective reduction of a nitro group to an amine under hypoxic conditions using rat liver microsomes.
• Detection of relaxivity enhancement in T(1)-weighted MRI.

Main Results:

• SAGds exhibited pH-dependent r(1) relaxivity linked to intramolecular chelation.
• A correlation was found between pK(a) changes and Hammett σ constants of aromatic substituents.
• The compound 4NO(2)2MeOSAGd showed a 1.8-fold r(1) relaxivity increment under hypoxia due to selective reduction.
• This relaxivity enhancement was clearly visualized in T(1)-weighted MR images.

Conclusions:

• The synthesized SAGds are the first hypoxia-sensitive MRI contrast agents.
• 4NO(2)2MeOSAGd functions as a 'smart' contrast agent, enabling MRI detection of hypoxia.
• This agent holds potential for improved diagnosis and monitoring of hypoxia-related diseases.